Background: Ischemic stroke (IS) is primarily caused by intricate inflammatory pathways and is a major global reason for mortality and disability. Patients with atrial fibrillation are treated with Rivaroxaban, a direct factor Xa inhibitor, to avoid stroke. This study looks at how certain genes are expressed in individuals with IS and how Rivaroxaban affects these genes and proteins.
Methods: Using gene expression data from the GEO database, dysregulated genes in IS patients were found. Peripheral blood mononuclear cells from 50 IS patients were used to measure the expression of CXCL8, CXCL2, and G0S2 90 days before and after Rivaroxaban therapy using RT-PCR and ELISA. The Enrichr online tool was used to perform a functional enrichment analysis.
Results: GEO2R analysis revealed that CXCL8, CXCL2, and G0S2 were significantly upregulated in IS samples compared to controls. Following Rivaroxaban therapy, the mRNA and protein levels of these genes showed a marked reduction, indicating a potential anti-inflammatory effect.
Conclusion: Rivaroxaban may control inflammatory responses in patients with IS, according to the study, which also reveals important genes implicated in IS. These results demonstrate the possibility of focused treatment approaches to reduce inflammation brought on by stroke.
Keywords: Gene Expression; Ischemic Stroke; PBMC; Rivaroxaban.
Copyright © 2025 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.